A phase 2 study of carperitide for kidney injury associated with allogeneic hematopoietic stem cell transplantation

A phase 2 study of carperitide for kidney injury associated with allogeneic hematopoietic stem cell transplantation - Carperitide trial for hematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028485

Enrollment

Registered

2017-08-30

Start date

2011-01-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allogeneic hematopoietic stem cell transplantation

Interventions

Carperitide treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Recipients of hematopoietic stem cell transplantation 2.meet eligibility criteria of the normal hematopoietic stem cells transplantation 3.do not have any severe organ damage 4.agreement is provided in a document

Exclusion criteria

Exclusion criteria: 1. Contraindicated] in the patient [attachment document with serious low blood pressure or the cardiogenic shock 2. Contraindicated] in the patient [attachment document with the RV myocardial infarction 3. Contraindicated] in the patient [attachment document with the dehydration 6. Chronic dialysis patient 7.ACE inhibitor, ARB treatment started within two weeks 8.patient received contrast media within three days 10,The patient who is inappropriate judged by the chief physician

Design outcomes

Primary

Measure	Time frame
serum creatinin at day 4	—

Secondary

Measure	Time frame
CCr Urine volume BUN Urine midkine, N-gal	—

Countries

Japan

Contacts

Public ContactHanda, Hiroshi

Gunma University, Graduate School of Medicine Medicine and Clinical Science

handahiroshi@gunma-u.ac.jp0272208166

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026